Sources: PharmaTimes Reuters
Novartis signs an agreement with Pfizer and BioNTech to help produce their vaccine. 2021-01-29
The Food and Drug Administration has approved the first treatment that genetically engineers patients' own blood cells to destroy acute lymphoblastic leukemia. The approval makes Novartis the proprietor of the first gene therapy to hit the U.S. market. 2017-08-30
The U.S. Food and Drug Administration (FDA) approves the country's first biosimilar drug, Zarxio (Europe: 2009, as Zarzio), made by Novartis. Biosimilars are a relatively new class of drugs designed to pave the way for less expensive versions of the complex biologics drug class, and they are not synthesized from chemicals like other drugs, but are made from living cells. Some well known biologics include Remicade and Enbrel for autoimmune diseases, and Herceptin and Avastin for cancer. Zarxio, used to prevent infection in cancer patients receiving chemotherapy, is a close copy of Neupogen, made by Amgen. 2015-03-6
India's Supreme Court rejects a plea by Novartis to patent an updated version of its cancer drug, Glivec (Imatinib), amid concerns that a patent could threaten access to cheap generic versions of drugs in poorer countries. 2013-04-1
In a case before the Supreme Court, the Indian Patent Office and pharmaceutical giant Novartis will present final arguments this week concerning the right to make and sell patented medicine. 2012-08-20